Author

James R. Eshleman

Johns Hopkins UniversityORCID 0000-0002-9274-8459Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Genomics· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Assay:long-read sequencing· 2 Research Focus:variant calling· 2 Research Focus:differential expression· 1 Assay:protein sequence· 1 Approach:statistical model· 1

Frequent Co-Authors

Alexis L. NorrisiD· 2 shared Winston TimpiD· 2 shared Angelo Michael De MarzoiD· 1 shared Corinne E. JoshuiD· 1 shared David Weiss· 1 shared Jessica Hicks· 1 shared Jiayun LuiD· 1 shared Josh Zhiyong Wang· 1 shared

Activity by Year

2016-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Alexis L. NorrisORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations with Race and Prostate Cancer Outcomes

Karen Sandell Sfanos, Rebecca Morton, Julia Flores, Rebecca Y. Sosa, Sarah E. Ernst, Luke A. Mummert, Jessica Hicks, Tamara Levin Lotan, Jiayun Lu, Yuezhou Jing, James R. Eshleman, Corinne E. Joshu, Angelo Michael De Marzo

The paper examines subclonal complete loss of CDKN1B in prostate cancer, finding higher prevalence in African American individuals and associations with worse outcomes.

Modern Pathology · Aug 12, 2026Peer-reviewedCancer Biology

IVT generation of guideRNAs for Cas9-enrichment Nanopore Sequencing

Timothy Gilpatrick, Josh Zhiyong Wang, David Weiss, Alexis L. Norris, James R. Eshleman, Winston Timp

The paper describes a method using in vitro transcribed guideRNAs for targeted nanopore sequencing to study structural variations in pancreatic cancer cell lines.

bioRxiv · Feb 7, 2023 · PreprintMolecular Biology

Nanopore sequencing detects structural variants in cancer

Alexis L. Norris, Rachael E. Workman, Yunfan Fan, James R. Eshleman, Winston Timp

This study demonstrates that nanopore sequencing can effectively detect structural variants in cancer, particularly large deletions, inversions, and translocations, with high sensitivity at low read counts.

Cancer Biology & Therapy · Jan 19, 2016Peer-reviewedGenomics